Health Rounds: Breast cancer is becoming less deadly for younger women, US study finds
May 2 (Reuters) - (To receive the full newsletter in your inbox for free sign up here)
Young U.S. women with breast cancer are not dying from the disease as often as a decade ago, researchers reported, opens new tab at the American Association for Cancer Research 2025, opens new tab meeting in Chicago.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
From 2010 to 2020, breast cancer deaths among women ages 20-49 declined significantly across all breast cancer subtypes and racial and ethnic groups, with marked declines starting after 2016, according to an analysis of data from the national Surveillance, Epidemiology, and End Results registry.
Overall, the breast cancer death rate in this age group fell from 9.70 per 100,000 women in 2010 to 1.47/100,000 in 2020.
The decline was sharper after 2016, likely due to advancements in treatment options, greater uptake of precision medicine, and expanded access to care and screening in women ages 40-49, study leader Adetunji Toriola of the Washington University School of Medicine in St. Louis said in a statement.
While breast cancer mortality declined in every racial and ethnic group, non-Hispanic Black women had the highest rate in both 2010 (16.56/100,000) and 2020 (3.41/100,000).
Non-Hispanic white women had the lowest rates in 2010 (9.18/100,000) and 2020 (1.16/100,000).
'We have made tremendous advances in reducing mortality from breast cancer in young women but there are still opportunities for improvements, especially in relation to eliminating disparities,' Toriola said.
'We must continue to perform impactful research to ensure further reduction in breast cancer mortality, including research into understanding the tumor biology and molecular mechanisms driving carcinogenesis and treatment response in younger women.'
GLP-1 DRUGS MAY CURB ATRIAL FIBRILLATION
GLP-1 drugs that are used to treat diabetes and have become wildly popular for weight loss, may also be useful for controlling the common heart rhythm disorder atrial fibrillation, researchers reported, opens new tab at the Heart Rhythm 2025, opens new tab meeting in San Diego.
Researchers looked at more than 2,500 patients with type 2 diabetes, atrial fibrillation and obesity at 170 U.S. Veterans Affairs medical centers.
Those who were receiving a GLP-1 drug experienced a 13% reduction in major AF-related events during a median follow-up of three years, compared to patients receiving other medications for their diabetes.
AF-related events included hospitalizations for the disorder, need for electroshock therapy to reset the heart rhythm, and ablation procedures to heat heart tissue in order to create scars that interrupt the electrical signals causing the arrhythmia.
Researchers did not identify the drugs being taken but common examples of GLP-1 medicines for diabetes include Novo Nordisk's (NOVOb.CO), opens new tab Ozempic, Rybelsus and Victoza, and Eli Lilly's (LLY.N), opens new tab Mounjaro and Trulicity.
Because patients were taking low doses of GLP-1 drugs, rather than higher doses used for weight loss, the results suggest the arrhythmia benefits are independent of any weight-loss benefit, the researchers noted.
The study was not designed to prove the GLP-1 drugs caused the reduction in AF events.
But study leader Dr. Varun Sundaram of the Louis Stokes Cleveland VA Medical Center and Case Western Reserve University said, "given the growing obesity epidemic and the rising prevalence of atrial fibrillation," it lays the foundation for a new approach to treating AF if larger trials confirm the potential benefits.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
19 hours ago
- Reuters
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's ( opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare". The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Reuters
19 hours ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
Telegraph
19 hours ago
- Telegraph
Dr James: Why ‘scanxiety' around cancer is common
Cancer being a most serious business inevitably evokes alarm and despondency. This might be mitigated, at least in part, by awareness of its favourable prognosis, particularly for those where it is diagnosed early. The combination of surgery to remove the tumour plus appropriate 'adjuvant' therapy should hopefully result in a complete cure in excess of 90 per cent of those with, for example, the common cancers of the bowel, prostate and breast. These excellent outcomes from 'treatment with curative intent' (as it is known) necessarily poses the question 'What next?'. Specifically, how frequently and thoroughly should doctors seek out with tests and scans the possibility it may have recurred in the small minority in whom it does? Patients' attitudes to this continuing ' routine surveillance ' are mixed. They certainly welcome the reassurance from those follow-up appointments – initially every few months and then at yearly intervals – that all is well, and the opportunity to discuss any concerns they may have. That reassurance may, however, be offset by trepidation in the weeks leading up to the appointment and particularly 'scanxiety', the apprehension that the findings of those scans might be inauspicious. 'It is all quite nerve-racking', comments a participant in a study of the phenomenon. 'Even if you are feeling fine, the fear of what might be revealed is most distressing'. While the rationale for 'routine surveillance' is entirely plausible – cancer recurrence detected before causing symptoms is likely to respond more readily to further treatment – the value of those repeat scans has recently been questioned. 'The empirical case is weak', notes Dr Gilbert Welch, commenting on the absence of the measurable benefit from the full canopy of investigations (ultrasound, bone scans, CT and MRI scans), which does not preclude the possibility they might be advantageous for some. The equivocal merits of such investigations is a common conundrum of modern medicine, but perhaps further encouragement to those 'treated with curative intent' to put their cancer diagnosis behind them and look optimistically towards the future. Coffins that inspire Many will have noted the diverting correspondence in this paper on embellishing funerals with idiosyncratic (and witty) allusions to the enthusiasms of the deceased. What more fitting tribute for a man who loved working his allotment than to bury him in his gardening clothes: or to place a jar of honey amongst the flowers on a beekeeper's coffin: or, for an adventurous climber, a compass 'to navigate his way to eternity'? Those seeking further inspiration might consider visiting the British Museum's enthralling Living and Dying gallery. Perhaps the most striking of the many exhibits are replicas of the tall, thin, elaborately decorated upright coffins of the North Australian Aborigines. The bones of the deceased painted in red ochre are broken up and placed in a tree trunk – hollowed out by termites – in which the spirit will travel to the Land of the Dead. Carvings on the exterior illustrating local landmarks ensure it will not get lost on the way, while family and friends dance around acting out the hazards that might be encountered. Following the ceremony, the coffin is left standing upright to be gradually eroded away by the elements. It is difficult to imagine a more uplifting – or ecological – send-off. A clever solution to athlete's foot Finally, my thanks to a couple of readers for passing on their experience of simple remedies for the intense itchiness of athlete's foot, where the standard antifungal creams, as a university lecturer comments, 'never work for very long'. Following his customary evening bath, he now rubs a tuft of cotton wool soaked in surgical spirit under and between his toes that keeps the skin 'a lovely healthy pink colour'. The next is an exercise in lateral thinking, the principal being that both athlete's foot and dandruff are primarily caused by a fungal infection. 'After soaking my feet in anti-dandruff shampoo for a few minutes, massaging it between the toes, the macerated skin floats away and the itching resolves', writes a Bath reader. 'Occasional supplement applications keep it in check'.
